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During the last years, the emergence of gram-negative bacteria resis-
tant to most available antibiotics all over the world has led to the read-
ministration of polymyxins B and E as ‘‘salvage’’ therapy in critically ill
patients [1]. The incidence of intensive care unit (ICU)–acquired infec-
tions caused by multidrug-resistant (MDR) gram-negative pathogens
that may cause pneumonia/ventilator-associated pneumonia (VAP), bac-
teremia, meningitis, urinary tract infections, and central venous cathe-
ter-related infections has been on the increase worldwide in the past 10
years [2,3]. For this reason, old antibiotics, such as polymyxin E (colistin)
or polymyxin B, have come back [4]. There have been many clinical re-
ports on the successful use of colistin or polymyxin B against infections
caused by MDR Pseudomonas aeruginosa, Acinetobacter baumannii, and
Klebsiella pneumonia strains. Studies investigating the minimum inhibitory
concentrations (MICs) of polymyxins against these MDR pathogens indi-
cate their activity.
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378 MICHALOPOULOS & FALAGASnosocomial-acquired infections are of great concern worldwide [5–9]. These
pathogens cause nosocomial infections and outbreaks, particularly among
critically ill patients hospitalized in ICUs or burn units and immunocompro-
mised patients [10]. The emergence of serious infections caused by MDR
pathogens in critically ill patients poses a treatment challenge. Carbape-
nems, antibiotics of choice for these pathogens, are becoming gradually
less useful in severely ill patients in whom outbreaks involving carbape-
nem-resistant A baumannii, P aeruginosa, K pneumoniae, and Enterobacter
aerogenes sp have been described [11,12].History of polymyxins
Polymyxins, a group of cationic polypeptide antibiotics consisting of five
different compounds (polymyxin A-E), were discovered in 1947 [13]. Colis-
tin, also known as polymyxin E, was the first antibiotic discovered in Japan,
in 1949 [14]. Only polymyxins B and E have been used in clinical practice.
Polymyxin B differs by only one amino acid from colistin. Colistin and poly-
myxin B are produced from Bacillus spp [15].
Colistin was synthesized nonribosomally by Bacillus polymyxa subspecies
colistinus [16]. It was first used in Japan and later in Europe during the
1950s and in the United States in 1959 [17]. The intravenous formulations
of colistin and polymyxin B were used for approximately two decades but
were gradually abandoned worldwide in the early 1970s because of the re-
ported severe toxicities [18–24]. During the past two decades, intravenous
administration of colistin was mainly restricted for the treatment of respira-
tory tract infections caused by MDR gram-negative pathogens in patients
with cystic fibrosis [25–27]. On the other hand, polymyxins have been
used worldwide in topical and ophthalmic solutions for decades.
In the recent literature, encouraging findings regarding the reuse of
colistin for the treatment of infections caused by MDR pathogens such as
P aeruginosa and A baumannii were first reported by Levin and colleagues
[28], followed by other reports that confirmed the favorable results of this
antibiotic [29]. Early therapy with inhaled colistimethate sodium (CMS),
the prodrug of colistin, is being used with good effectiveness in preventing
deterioration in patients who have cystic fibrosis and chronic infection. Sev-
eral chronically infected patients who have cystic fibrosis also have been
treated successfully with 3-month courses of intravenous CMS [30].Forms of colistin
Two forms of colistin are available commercially: CMS (also called so-
dium colistin methanesulphonate, colistin methanesulfonate, colistin sulfo-
methate, or colistimethate), which is used for parenteral and inhalation
therapy, and colistin sulfate, which is used orally and for topical use. Great
379COLISTIN AND POLYMYXIN B IN CRITICAL CAREcare is needed to avoid confusion between colistin (base) and CMS; it is
essential not to use the terms interchangeably. It has been demonstrated re-
cently that CMS is a prodrug of colistin [31].
Both preparations are hydrolysed to a complex mixture of partially sul-
phonated derivatives, which possess varying antibacterial activities, and
colistin itself. Colistin and CMS have different structures; colistin is a poly-
cation and CMS is a polyanion at physiologic pH [32]. Colistin is two- to
fourfold more active against P aeruginosa than CMS. The presence of colis-
tin in plasma from patients who have cystic fibrosis shortly after intravenous
administration of CMS has been demonstrated, as has the rapid conversion
of CMS to colistin after intravenous administration of CMS to rats [33]. It is
presumed that plasma or serum samples contain many intermediate metab-
olites of CMS. The complex chemistry of CMS and the differences between
CMS and colistin in terms of stability, pharmacokinetics, and pharmacody-
namics have not been fully recognized [34].Mechanism of action
Polymyxins are a group of polypeptide cationic antibiotics that consist of
a cyclic decapeptide molecule, positively charged and linked to a fatty acid
chain that has been found to be either 6-methyl-octanic acid or 6-methyl-
eptanoic acid. The main difference between the molecules of polymyxin B
and E is in the amino acid components [35]. The cationic molecules of poly-
myxin B and colistin compete and displace Ca2þ and Mg2þ ions, which nor-
mally stabilize the lipopolysaccharide molecule of the outer membrane of
gram-negative bacteria. They are comprised of a polycationic peptide ring
that contains ten amino acids and a fatty acid side chain. Both of these com-
pounds are bactericidal, targeting the bacterial cell wall, disrupting mem-
brane permeability, and ultimately leading to cell death.
The polymyxins exert their bactericidal activity by binding to the bacte-
rial cell membrane and disrupting its permeability, which results in leakage
of intracellular components. They also have antiendotoxin activity [36].
These agents are rapidly bactericidal against many gram-negative bacteria.
The polymyxin antimicrobials are poorly absorbed from the gastrointestinal
tract. Colistin concentrates in the liver, kidney, muscle, heart, and lungs but
does not consistently cross the blood–brain barrier in noninflamed menin-
ges. The poor dialyzability of the polymyxins may be caused by their large
molecular size and not their plasma or tissue-binding ability [37]. Poly-
myxins are excreted primarily by the kidneys. Pharmacokinetic studies in
the 1960s demonstrated that the serum half-life of these drugs increases
from 6 hours or less in individuals with normal renal function to 48 hours
or more in anuric patients [38,39].
Owen and colleagues [40] examined recently the in vitro pharmacody-
namics of colistin against A baumannii clinical isolates. They found that
380 MICHALOPOULOS & FALAGAScolistin showed rapid killing in a concentration-dependent manner. Colistin
exhibited modest postantibiotic effect, however. Their results suggest that
monotherapy with CMS, the parenteral form of colistin, and long dosage
intervals (eg, 24 hours) may be problematic for treatment of infections
caused by colistin-heteroresistant A baumannii, although these findings
should be supplemented by clinical studies.
Colistin has good activity against Acinetobacter spp (MIC90 % 2 mg/L),
K pneumoniae (MIC90 % 1 mg/L), E coli (MIC90 % 2 mg/L), P aeruginosa
(MIC90 % 4 mg/L) [41], and Enterobacter spp (MIC50 % 1 mg/L). It also
may be active against some strains of Shigella spp (MIC90 % 0.5 mg/L),
Salmonella spp (MIC90 % 1 mg/L), Citrobacter spp (MIC90 % 1 mg/L),
and E coli (MIC90% 1 mg/L). No useful activity was demonstrated against
Providentia spp or Serratia spp [42]. Colistin has a rapid concentration-
dependent bactericidal activity at concentrations between 3 and 200 mg/L,
although there is no clearly increased colistin activity at concentrations
above 18 mg/L. Polymyxin B exhibits good activity against P aeruginosa
at MIC90 % 4 mg/L [43].Dosage of colistin and polymyxin B in critical care
Colistin dosing has ranged from 2.5 to 5.0 mg/kg/d in patients with nor-
mal renal function and is usually given two to four times a day [44]. In the
United Kingdom, for adult patients and children older than 12 years who
have normal renal function and body weight more than 60 kg, a dosing reg-
imen of 240 to 480 mg (3–6 million IU) of CMS per day in three divided
doses is recommended. In patients who have normal renal function and
body weight 60 kg or less, 4 to 6 mg/kg (50,000–75,000 IU/kg) of CMS
per day divided in three doses is recommended. It is remarkable that there
is a substantial difference in the recommended doses of the European and
US products. The recommended upper limit dosage for a 60-kg patient
with normal renal function is 480 mg of CMS per day for the European
product and approximately 800 mg of CMS per day for the US product
[45]. Several clinical studies from Europe reported that in critically ill adult
patients with normal renal function and body weight more than 60 kg, CMS
was administered intravenously in a dose of 9 million IU divided into three
equal doses.
The dosage of intravenous polymyxin B recommended by the manufac-
turer is 1.5 to 2.5 mg/kg/d (15,000–25,000 IU/kg/d) divided into two equal
doses for adults and children older than 2 years with normal renal function.
One milligram of polymyxin B is equal to 10,000 IU.
Dosage adjustments are recommended for patients with mild to moderate
renal dysfunction. Specifically, when the serum creatinine level is 1.3 to
1.5 mg/dL, 1.6 to 2.5 mg/dL, or above 2.6 mg/dL, the recommended dosage
of intravenous colistin for serious infections is 2 million IU every 12 hours,
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cessitates dialysis, the recommended intravenous dosages of CMS are 2 to
3 mg/kg after each hemodialysis treatment [46] and 2 mg/kg daily during
peritoneal dialysis [47]. Recommendations for dosage adjustment of poly-
myxin B in the presence of renal impairment have not been well established.
It is remarkable to emphasize the existing confusion regarding the correct
dosing of colistin worldwide. To avoid confusion regarding dosing of colistin,
it is preferable to use a dosing system based on international units. The use of
international units for colistin dosing helps decrease confusion related to var-
ious formulations of this regimen [48]. Pure colistin base has been assigned
a potency of 30,000 IU/mg, whereas CMS has a potency of 12,500 IU/mg.
It should be noted that the formulation manufactured by Alpharma A/S
(Copenhagen, Denmark) and distributed by Forest Laboratories (Kent,
United Kingdom) in Europe contains 80 mg of CMS (1 million IU).
So far, most investigations on the pharmacodynamics of the polymyxins
have focused on colistin, and less is known about the pharmacodynamics of
polymyxin B [49]. Better understanding of the pharmacodynamics of poly-
myxin B may help to determine its exact dose rationally to optimize patient
outcomes and avoid resistance. Recently, Tam and colleagues [50] examined
the pharmacodynamics of polymyxin B against P aeruginosa and suggested
that the bactericidal activity of this regimen was concentration dependent
and seemed to be related to the ratio of the area under the concentration-
time curve to the MIC. Investigations for the determination of the optimal
dosage of these regimens in different subpopulations of patients are urgently
required, however.Administration of colistin and polymyxin B in critical care
The incidence of infections caused by pathogens resistant to b-lactam
agents, cephalosporins, aminoglycosides, and quinolones has increased
sharply in recent years. The prevalence of such resistant pathogens in ICUs
is as high as 21.8% in large teaching hospitals [51]. They are associated
with high mortality rates. For example, the mortality rates for A baumannii
infections have been reported to be 52% for bacteremias and 23% to 73%
for pneumonia [52].
Most of the reintroduction of polymyxins in critical care during the last
few years is related to colistin. The polymyxins are active against selected
gram-negative bacteria, including Acinetobacter sp, P aeruginosa, Klebsiella
sp, and Enterobacter sp. These pathogens can cause a multitude of ICU-
acquired infections, including pneumonia/VAP, bacteremia, meningitis, uri-
nary tract infections, and skin and soft tissue infections. Isolates resistant to
almost all commercially available antimicrobials have been identified, thus
limiting treatment options. The development of new agents against MDR
gram-negative bacteria and reappraisal of older compounds (ie, polymyxins)
are necessary for the optimal treatment of these pathogens.
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threatening nosocomial acquired infections caused by MDR gram-negative
pathogens in adult patients. However, there are recent reports on the intra-
venous administration of these agents in children [53].Administration of colistin in ventilator-associated pneumonia
Garnacho-Montero and colleagues [29] administered intravenous CMS
in 21 of 35 patients with VAP caused by MDR A baumannii strains suscep-
tible exclusively to colistin. The rest of patients (n ¼ 14) had similar
APACHE II scores at the time of ICU admission and Sequential Organ
Failure Assessment scores at time of VAP diagnosis and received merope-
nem based on sensitivity tests and MICs. The observed outcomes, including
in-hospital mortality, VAP-related mortality, and clinical cure, were similar
in the compared groups. VAP was considered clinically cured in 57% of
cases in both groups.
We reported our experience with the management of ICU-acquired pneu-
monia, namely VAP, due to MDR gram-negative bacteria (P aeruginosa and
A baumannii) in 45 patients who had no history of cystic fibrosis. All pa-
tients received intravenous CMS in combination with broad-spectrum anti-
biotics, such as carbapenems, piperacillin/tazobactam, and ampicillin/
sulbactam. A subset of patients also received aerosolized CMS at a mean
daily dosage of 3.2 million IU (256 mg) divided in three equal doses as an
adjunctive to the intravenous treatment. The observed clinical cure was 30
of 45 patients (66.7%), and the survival rate was 75.6% [54].
In a prospective cohort study, Reina and colleagues [55] examined the
safety and effectiveness of colistin in ICU-acquired infections caused by
A baumannii and P aeruginosa in 185 ICU patients. Patients received colistin
(n ¼ 55) or other antibiotics (n ¼ 130), mainly carbapenems (81%). The two
groups were similar in age, APACHE II, medical status, and Sequential Or-
gan Failure Assessment score. The most frequent infection was VAP: 53%
in colistin versus 66% in noncolistin group. Clinical cure on ICU day 6 of
treatment was observed in 15% of colistin group and in 17% of noncolistin
group. The mortality rates were 29% and 24%, respectively (P ¼ NS).
In a retrospective cohort study we also evaluated the effectiveness and
nephrotoxicity of intravenous colistin monotherapy versus intravenous co-
listin/b-lactam combination in a group of patients with MDR gram-negative
bacterial infections. Fourteen patients received colistin monotherapy and 57
received colistin/meropenem. The groups were similar in terms of demo-
graphics and comorbidity. Most patients suffered from pneumonia/VAP.
No statistically significant differences were found regarding clinical response
(cure and improvement) of the infection (12/14 [85.7%] versus 39/57
[68.4%], P ¼ .32) and development of nephrotoxicity (0/14 [0%] versus
4/57 [7%], P ¼ .32) between these two groups of patients. A favorable
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therapy compared with colistin/meropenem (0/14 [0%] versus 21/57
[36.8%], P ¼ .007), even after adjusting for the variables for which statisti-
cally significant differences between the compared groups were found [56].
Further studies are needed to clarify the role of colistin monotherapy versus
combinations of colistin with various antibiotics.
It should be mentioned that colistin should be used with caution to help
preserve its activity as long as possible. It is interesting that the finding that
prolonged use of combination of carbapenems (O 20 days) and colistin
(O 13 days) was an independent predictor for pandrug-resistant P aerugi-
nosa VAP [57].Administration of colistin in bacteremia/sepsis
Markou and colleagues [58] used 26 courses of intravenous colistin in 24
ICU patients with sepsis. Clinical response was observed for 73% of the
treatments. Deterioration of renal function was found in 14.3% of patients,
whereas survival at 30 days was 57.7%. Karabinis and colleagues [59] re-
ported the successful management of a patient with bacteremia/septic shock
caused by K pneumoniae in whom they administered colistin intravenously
in a dosage of 9 million IU/d (2.5 mg/kg, divided into three doses). We
used continuous intravenous colistin in a critically ill patient with bacter-
emia caused by a multiresistant A baumannii strain susceptible only to colis-
tin; this approach led to the cure of this life-threatening infection [60].
Recently, we reported that the mortality rate was acceptable (35.7%)
in critically ill patients with ICU-acquired bacteremia caused by MDR
A baumannii who received intravenously colistin and meropenem, based
on sensitivity tests and MICs. On the contrary, the mortality rate was
56% in the group of patients with bacteremia caused by A baumannii strains
susceptible only to colistin [61].Administration of colistin in meningitis
Berlana and colleagues [62] administered colistin (intravenously, intramus-
cularly, inhaled, or intrathecally) in 80 patients infected with MDR A bau-
mannii (86%) or P aeruginosa (14%). In 41 patients (51%), the episodes
were caused by A baumannii strains susceptible exclusively to colistin. The
causative organisms were cleared in 92% of the patients from whom post-
treatment repeat specimens were obtained. The in-hospital mortality rate
was 18% (14 patients).
A systematic review of the literature showed recently that 64 episodes of
gram-negative meningitis (34 in adults) were treated with a combination of
systemic and local polymyxins (25 episodes) or with polymyxin monother-
apy via the intraventricular or intrathecal route (11 episodes). Cure was
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P aeruginosa, and in 10 of 11 episodes (91%) caused by Acinetobacter
spp. Toxicity related to local administration of polymyxins was noted in
17 of 60 (28%) patients. The most common complication was meningeal ir-
ritation (12 cases). Discontinuation of treatment was necessary in four ep-
isodes and dose reduction in four episodes; irreversible toxicity was not
reported [63].Routes of administration
Another point of interest is that routes of colistin administration other
than the intravenous one may have clinical value, including aerosolized
(nebulized) administration of the antibiotic to patients with severe pneumo-
nia or VAP. The value of aerosolized colistin in the prevention and treat-
ment of infections caused by P aeruginosa strains already has been proved
for patients with cystic fibrosis [64].
Inhaled CMS or polymyxin B has been used in combination with conven-
tional intravenous antibiotic treatment in critically ill patients with VAP
caused by MDR gram-negative pathogens [65,66]. Although the number
of patients receiving aerosolized colistin so far is limited, it was thought
that this supplementary therapy is associated with improved outcome, sug-
gesting that this approach merits further evaluation. The recommended dos-
age of nebulized CMS for adults is 2 to 4 million IU/d usually divided into
three or four equal doses [67–69].
Intraventricular or intrathecal administration of colistin may prove to be
a life-saving intervention for patients with meningitis caused by MDR
gram-negative pathogen not responding to intravenous treatment with an-
timicrobial agents, including colistin. Several case reports in the literature
indicate the success of this approach [70–73]. The recommended dosages
in this case range from 3.75 mg to 10 mg CMS per day [74,75]. Some pa-
tients received intraventricular or intrathecal CMS treatment at a dose of
10 to 20 mg/d for a mean of 20 days, without presenting any adverse events.
Direct instillation of colistin into the central nervous system may cause
chemical meningitis or ventriculitis [76]. Issues such as dose and duration
of treatment remain unresolved and require further evaluation in prospec-
tive controlled trials.Adverse events of polymyxin B and colistin
The major adverse events of polymyxins are nephrotoxicity, neurotoxic-
ity, and neuromuscular blockade. Polymyxins can cause a direct toxic effect
in kidneys that results in acute tubular necrosis and renal insufficiency or
failure, manifested by increase in serum urea and creatinine levels associated
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cause hematuria, proteinuria, and cylindruria. Nephrotoxicity of CMS
seems to be less compared with that associated with polymyxin B. Concom-
itant administration of other potential nephrotoxic agents increases the like-
lihood for development of acute renal failure. When the administration of
a polymyxin is associated with renal dysfunction, early discontinuation of
this regimen is necessary. Appropriate fluid management to maintain a rea-
sonable central venous pressure value, close monitoring of serum electro-
lytes, and quick diuresis by administration of mannitol (resulting in renal
clearance of all nephrotoxic drugs) are necessary [77].
We recently prospectively evaluated the nephrotoxicity associated with the
intravenous administration of colistin in 21 patients for at least 7 days. The
mean daily dose of colistin was 5.5 million IU, whereas the mean duration
of treatment was 15 days (range 7–54 days). Only 3 of 21 patients (14.3%)
developed nephrotoxicity during treatment with CMS [78].We also examined
the toxicity of colistin after 19 courses of prolonged (defined asO 4 weeks)
intravenous administration in 17 ICU patients. Mean daily dosage was
4.4 million IU, and mean duration of administration was 43.4 days. Median
serum creatinine value increased by 0.25 mg/dL during the treatment period
compared with baseline (P ! .001). No apnea or other evidence of neuro-
muscular blockade was noted in this group of patients [79].
The neurotoxic effects include oral and perioral paresthesia, headache,
ataxia, vertigo, visual disturbances, confusion, lower limb weakness, and va-
somotor instability [17]. These agents also can cause a reversible neuromus-
cular blockade leading to respiratory failure. Between 1964 and 1973, there
are at least eight case reports in the literature correlating the intramuscular
administration of polymyxins with development of episodes of respiratory
apnea [80,81]. It is remarkable that all recently performed studies in criti-
cally ill patients with nosocomial-acquired infections caused by MDR
gram-negative pathogens who received large doses of colistin did not report
serious neurotoxicity correlated with the administration of this regimen. We
could not identify reports in the literature over the past 15 years or more
regarding episodes of neuromuscular blockade or apnea induced by
polymyxins.
Other rare complications related to polymyxin administration are allergic
reactions (contact dermatitis, itching, and rash), ototoxicity, drug fever, and
gastrointestinal disturbances [82]. Complications related to administration
of aerosolized colistin are sore throat, cough, bronchoconstriction even in
patients with no history of bronchial asthma or atopy (due to chemical stim-
ulation, liberation of histamine, allergy in the airways, irritation from chem-
icals the foam that is produced during nebulization, and hyperosmolarity in
the airway), and chest tightness [83]. Bronchoconstriction usually requires
discontinuation of the medication and administration of bronchodilators.
It should be emphasized that solutions of colistin made for aerosolized treat-
ment should be administered immediately after their preparation.
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Sobieszczyk and colleagues [84] examined retrospectively the clinical and
microbiologic efficacy and safety profile of polymyxin B in the treatment of
MDR gram-negative bacterial infections of the respiratory tract. Twenty-
five critically ill patients received a total of 29 courses of polymyxin B ad-
ministered in combination with another antimicrobial agent. Patients were
treated with intravenous and aerosolized polymyxin B. Mean duration of
polymyxin B therapy was 19 days (range 2–57 days). End of treatment mor-
tality was 21%, and overall mortality at discharge was 48%. Nephrotoxicity
was observed in three patients (10%) and did not result in discontinuation
of therapy. The authors concluded that polymyxin B in combination with
other antimicrobials can be considered a reasonable and safe treatment
option for MDR gram-negative respiratory tract infections in the setting
of limited therapeutic options. Similar good results were reported by Hollo-
way and colleagues [85] after administration of intravenous polymyxin B in
29 critically ill patients with infections caused by MDR A baumannii. The
observed clinical cure was 76%, whereas crude mortality rate was 27%.
Sarria and colleagues [86] reported their experience from the use of intra-
venous polymyxin B in a patient with A baumannii sepsis and acute renal
failure that required continuous venovenous hemodialysis. The patient
was treated successfully with intravenous polymyxin B.Summary
Recent studies in critically ill patients who received intravenous poly-
myxins for the treatment of serious P aeruginosa and A baumannii infections
of various types, including pneumonia, bacteremia, and urinary tract infec-
tions, have led to the conclusion that these antibiotics have acceptable effec-
tiveness and considerably less toxicity than was reported in old studies.
The frequency of nephrotoxicity and severity of neurotoxicity seem to be
substantially less than previously believed. Recently, a significant increase
in the data gathered on colistin has focused on its chemistry, antibacterial
activity, mechanism of action and resistance, pharmacokinetics, pharma-
codynamics, and new clinical application. Colistin has attracted more inter-
est during the last years because of its significant activity against MDR
P aeruginosa, A baumannii, and K pneumoniae strains responsible for
ICU-acquired infections in critically ill patients. It is likely that colistin
will be an important antimicrobial option against MDR gram-negative bac-
teria for at least several years [32]. It should be mentioned that no well-de-
signed, randomized controlled studies have been conducted to evaluate the
effectiveness and safety of polymyxins for the treatment of life-threatening,
ICU-acquired infections caused by MDR gram-negative pathogens, such as
P aeruginosa, A baumannii, and K pneumoniae. For this reason, such trials
are urgently needed.
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equate colistin use may have contributed to the emergence of colistin resis-
tance among P aeruginosa, A baumannii, and K pneumoniae isolates,
potentially increasing morbidity and mortality rates in critically ill patients
and necessitating prudent use of colistin [87]. For this reason, the empiric
use of colistin should be limited to institutions in which there is recognized
infection caused by MDR gram-negative bacilli [88].References
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